A carregar...
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses
INTRODUCTION: Ibrutinib, a first-in-class covalent inhibitor of Bruton’s tyrosine kinase (BTK), is approved in many countries for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and for previously untreated disease with a 17p deletion and, most recently, as a frontline therap...
Na minha lista:
| Publicado no: | Expert Opin Drug Metab Toxicol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5391303/ https://ncbi.nlm.nih.gov/pubmed/27686109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17425255.2016.1239717 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|